Sekar Kathiresan - Jun 16, 2021 Form 3 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Andrew Ashe, Attorney-in-Fact
Stock symbol
VERV
Transactions as of
Jun 16, 2021
Transactions value $
$0
Form type
3
Date filed
6/16/2021, 07:42 PM
Next filing
Jun 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VERV Common Stock 404K Jun 16, 2021 Direct
holding VERV Common Stock 81K Jun 16, 2021 Kathiresan Family 2021 Irrevocable Trust
holding VERV Common Stock 81K Jun 16, 2021 Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VERV Stock Option (right to buy) Jun 16, 2021 Common Stock 432K $8.24 Direct F1
holding VERV Stock Option (right to buy) Jun 16, 2021 Common Stock 675K $2.87 Direct F2
holding VERV Stock Option (right to buy) Jun 16, 2021 Common Stock 189K $1.39 Direct F3
holding VERV Stock Option (right to buy) Jun 16, 2021 Common Stock 432K $1.39 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 12, 2021 for 431,988 shares. 25% of the shares underlying the option will vest on February 1, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until February 1, 2025.
F2 The option was granted on September 16, 2020 for 674,982 shares. 25% of the shares underlying the option will vest on September 16, 2021, and the remainder are scheduled to vest in equal monthly installments thereafter until September 16, 2024.
F3 The option was granted on April 15, 2019 for 188,995 shares. 25% of the shares underlying the option vested on March 25, 2021, and the remainder are scheduled to vest in equal monthly installments thereafter until March 25, 2024.
F4 The remaining shares underlying this option, which was granted on April 15, 2019, vest in equal monthly installments thereafter until July 22, 2023.

Remarks:

Exhibit Index: 24.1 Power of Attorney